ETF Holdings Breakdown of PLRX

PLRX institutional holdings

The following institutional investment holdings of PLRX have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	37,499	USD 67,498	1.80
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	37,499 0.3%	USD 67,498 7.5%	1.80
Total =		74,998	USD 134,996

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with PLRX

Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) PT at $8.19

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has earned an average recommendation of “Hold” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among […] - 2025-09-05 02:16:53

Comparing Pliant Therapeutics (NASDAQ:PLRX) & CARGO Therapeutics (NASDAQ:CRGX)

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Profitability This table compares Pliant Therapeutics and […] - 2025-08-15 04:22:53

Federated Hermes Inc. Raises Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Federated Hermes Inc. increased its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 1,557.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,209 shares of the company’s stock after acquiring an additional 55,637 shares during the period. Federated Hermes Inc.’s […] - 2025-08-11 04:54:59

Piper Sandler Cuts Pliant Therapeutics (NASDAQ:PLRX) Price Target to $4.00

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective cut by Piper Sandler from $17.00 to $4.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the stock. Pliant Therapeutics Stock Performance NASDAQ:PLRX opened at $1.66 on Friday. The stock has a 50-day simple moving average of $1.44 and […] - 2025-08-11 03:08:44

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $8.19 Consensus Target Price from Brokerages

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been assigned an average rating of “Hold” from the thirteen ratings firms that are currently covering the company, Marketbeat reports. Twelve analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among […] - 2025-08-11 02:12:52

XTX Topco Ltd Makes New $630,000 Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

XTX Topco Ltd bought a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 466,842 shares of the company’s stock, valued at approximately $630,000. XTX Topco Ltd owned about 0.76% of Pliant Therapeutics […] - 2025-08-06 05:17:07

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Hold” by Analysts

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received an average rating of “Hold” from the twelve ratings firms that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a hold rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last […] - 2025-05-22 02:34:47

Renaissance Technologies LLC Cuts Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Renaissance Technologies LLC lessened its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 72.5% in the 4th quarter, Holdings Channel reports. The firm owned 27,800 shares of the company’s stock after selling 73,400 shares during the period. Renaissance Technologies LLC’s holdings in Pliant Therapeutics were worth $366,000 at the end of […] - 2025-05-05 04:30:58

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $13.31 Consensus PT from Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the firm, Marketbeat reports. Twelve equities research analysts have rated the stock with a hold recommendation. The average twelve-month target price among analysts that have covered the stock in […] - 2025-04-30 02:47:01

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Legal & General Group Plc

Legal & General Group Plc increased its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 21.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 52,961 shares of the company’s stock after purchasing an additional 9,370 shares during the period. Legal & General Group Plc’s holdings in Pliant Therapeutics were worth $697,000 […] - 2025-04-29 05:34:50

American Century Companies Inc. Purchases 9,944 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)

American Century Companies Inc. raised its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 10.9% during the fourth quarter, Holdings Channel reports. The fund owned 100,849 shares of the company’s stock after buying an additional 9,944 shares during the period. American Century Companies Inc.’s holdings in Pliant Therapeutics were worth $1,328,000 […] - 2025-04-11 04:32:49

HC Wainwright Reaffirms “Neutral” Rating for Pliant Therapeutics (NASDAQ:PLRX)

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. A number of other research analysts also recently weighed in on PLRX. Citigroup lowered their price target on Pliant Therapeutics from $4.00 to $1.50 and set a “neutral” rating on the […] - 2025-03-20 04:44:46

AlphaQuest LLC Reduces Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

AlphaQuest LLC lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 73.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,681 shares of the company’s stock after selling 18,890 shares during the quarter. AlphaQuest LLC’s holdings in Pliant […] - 2025-03-19 06:20:56

Wells Fargo & Company Has Lowered Expectations for Pliant Therapeutics (NASDAQ:PLRX) Stock Price

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective cut by Wells Fargo & Company from $4.00 to $3.00 in a report released on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock. Several other brokerages have also recently issued reports on PLRX. Leerink Partners cut Pliant Therapeutics from an […] - 2025-03-07 07:07:07

Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. Several other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. downgraded Pliant Therapeutics from an “overweight” rating to a “neutral” rating […] - 2025-03-06 08:47:03

Royal Bank of Canada Has Lowered Expectations for Pliant Therapeutics (NASDAQ:PLRX) Stock Price

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) had its price target decreased by equities research analysts at Royal Bank of Canada from $4.00 to $3.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s target price indicates a potential upside of […] - 2025-03-06 08:13:24

Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $1.50 by Analysts at Citigroup

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock. PLRX has been the subject of several other reports. Canaccord Genuity Group reissued a “hold” rating and issued a $4.00 […] - 2025-03-05 08:07:38

Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Sector Perform Rating by Royal Bank of Canada

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Monday, MarketBeat Ratings reports. They presently have a $4.00 price objective on the stock, down from their prior price objective of $45.00. Royal Bank of […] - 2025-02-12 04:58:57

Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by HC Wainwright

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Monday, MarketBeat Ratings reports. Pliant Therapeutics Trading Down 15.0 % Shares of Pliant Therapeutics stock opened at $2.61 on Monday. The firm’s 50 day moving average is $12.42 […] - 2025-02-12 04:58:50

Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wells Fargo & Company

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $4.00 price target on the stock, down from their previous price target of $41.00. Wells Fargo […] - 2025-02-12 04:58:50

Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Neutral Rating by Citigroup

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by investment analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $4.00 price objective on the stock, down from their prior price objective of $40.00. Citigroup’s target price would […] - 2025-02-12 04:58:48

Pliant Therapeutics Pauses Enrollment And Dosing In BEACON-IPF Trial, Stock In Freefall

(RTTNews) - Pliant Therapeutics Inc. (PLRX) suffered a major blow on Friday, with its shares tumbling nearly 35% in regular trading and plunging another 58% to $3.27 in after-hours, following an update on its BEACON-IPF trial. - 2025-02-10 04:56:26

China Universal Asset Management Co. Ltd. Increases Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

China Universal Asset Management Co. Ltd. boosted its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 10.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,903 shares of the company’s stock after purchasing an additional 1,209 shares during the quarter. China Universal […] - 2025-02-04 07:15:10

2,490 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by R Squared Ltd

R Squared Ltd purchased a new position in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the 4th quarter, Holdings Channel reports. The firm purchased 2,490 shares of the company’s stock, valued at approximately $33,000. Several other institutional investors and hedge funds have also recently bought and sold shares of PLRX. Atria Investments […] - 2025-02-04 06:29:09

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 27.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,729 shares of the company’s stock after buying an additional 6,579 shares during the quarter. SG Americas Securities LLC’s […] - 2025-02-03 06:58:54

Back to Listing

Disclaimer